Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

[Cancer medicines: reasons for anger].

Gonçalves A, Maraninchi D, Vernant JP.

Rev Prat. 2017 Feb;67(2):141-145. French.

PMID:
30512845
2.

[Anticancer drugs: Which prices for therapeutic innovations?].

Gonçalves A, Maraninchi D, Marino P.

Bull Cancer. 2016 Apr;103(4):361-7. doi: 10.1016/j.bulcan.2016.03.002. Epub 2016 Apr 1. Review. French.

PMID:
27045535
3.

[The French medecine pricing committee].

Giorgi D.

Ann Pharm Fr. 2017 Sep;75(5):373-384. doi: 10.1016/j.pharma.2017.04.005. Epub 2017 Jun 2. French.

PMID:
28583317
4.

[Conditional pricing for innovative medicines in France: stop telling about risk-sharing!].

Megerlin F.

Ann Pharm Fr. 2013 Sep;71(5):291-301. doi: 10.1016/j.pharma.2013.08.004. Epub 2013 Sep 7. French.

PMID:
24075700
5.

Is there transparency in the pricing of medicines in the South African private sector?

Bangalee V, Suleman F.

S Afr Med J. 2018 Feb 1;108(2):82-83. doi: 10.7196/SAMJ.2017.v108i2.12815.

6.

American Society of Clinical Oncology guidance statement: the cost of cancer care.

Meropol NJ, Schrag D, Smith TJ, Mulvey TM, Langdon RM Jr, Blum D, Ubel PA, Schnipper LE; American Society of Clinical Oncology.

J Clin Oncol. 2009 Aug 10;27(23):3868-74. doi: 10.1200/JCO.2009.23.1183. Epub 2009 Jul 6.

PMID:
19581533
7.

A comparative analysis of two contrasting European approaches for rewarding the value added by drugs for cancer: England versus France.

Drummond M, de Pouvourville G, Jones E, Haig J, Saba G, Cawston H.

Pharmacoeconomics. 2014 May;32(5):509-20. doi: 10.1007/s40273-014-0144-z.

PMID:
24599784
8.

Price comparison of high-cost originator medicines in European countries.

Vogler S, Zimmermann N, Babar ZU.

Expert Rev Pharmacoecon Outcomes Res. 2017 Apr;17(2):221-230. doi: 10.1080/14737167.2016.1223543. Epub 2016 Oct 11.

PMID:
27658050
9.

[Evolution of reimbursement of high-cost anticancer drugs: Financial impact within a university hospital].

Baudouin A, Fargier E, Cerruti A, Dubromel A, Vantard N, Ranchon F, Schwiertz V, Salles G, Souquet PJ, Thomas L, Bérard F, Nancey S, Freyer G, Trillet-Lenoir V, Rioufol C.

Bull Cancer. 2017 Jun;104(6):538-551. doi: 10.1016/j.bulcan.2017.01.006. Epub 2017 Feb 23. French.

PMID:
28237353
10.

[The French medecine pricing committee and the medicine economic policy: Rules and competences].

Giorgi D.

Ann Pharm Fr. 2017 Sep;75(5):359-372. doi: 10.1016/j.pharma.2017.04.001. Epub 2017 May 15. French.

PMID:
28522031
11.

Early access to health products in France: Major advances of the French "Conseil stratégique des industries de santé" (CSIS) to be implemented (modalities, regulations, funding).

Albin N, Chassagnol F, Bergmann JF; participants of Giens XXXIV Round Table “Organisational and regulatory aspects”; with collaboration.

Therapie. 2019 Feb;74(1):103-117. doi: 10.1016/j.therap.2018.12.002. Epub 2018 Dec 13.

PMID:
30745156
12.

Challenging the soaring price of cancer medicines: a call for equity and transparency.

Gonçalves A, Maraninchi D, Vernant JP.

Ann Oncol. 2016 Sep;27(9):1812-3. doi: 10.1093/annonc/mdw195. Epub 2016 May 6. No abstract available.

PMID:
27154419
13.

[Risk sharing methods in middle income countries].

Inotai A, Kaló Z.

Acta Pharm Hung. 2012;82(1):43-52. Review. Hungarian.

PMID:
22570986
14.

Drug pricing and value in oncology.

Danzon PM, Taylor E.

Oncologist. 2010;15 Suppl 1:24-31. doi: 10.1634/theoncologist.2010-S1-24.

15.

Controlling the cost of innovative cancer therapeutics.

Malik NN.

Nat Rev Clin Oncol. 2009 Sep;6(9):550-2. doi: 10.1038/nrclinonc.2009.113. Review.

PMID:
19707244
16.

Developing and paying for medicines for orphan indications in oncology: utilitarian regulation vs equitable care?

Davies JE, Neidle S, Taylor DG.

Br J Cancer. 2012 Jan 3;106(1):14-7. doi: 10.1038/bjc.2011.544. Review.

17.
18.

Market spiral pricing of cancer drugs.

Light DW, Kantarjian H.

Cancer. 2013 Nov 15;119(22):3900-2. doi: 10.1002/cncr.28321. Epub 2013 Sep 3. No abstract available.

19.

Cancer Drugs: An International Comparison of Postlicensing Price Inflation.

Savage P, Mahmoud S, Patel Y, Kantarjian H.

J Oncol Pract. 2017 Jun;13(6):e538-e542. doi: 10.1200/JOP.2016.014431. Epub 2017 Feb 7.

PMID:
28605615
20.

Generic medicine pricing in Europe: current issues and future perspective.

Simoens S.

J Med Econ. 2008;11(1):171-5. doi: 10.3111/13696990801939716.

PMID:
19450118

Supplemental Content

Support Center